Dennis J. Slamon, MD, PhD

Dennis J. Slamon, MD, discusses the rationale of the phase 3 NATALEE trial and ribociclib for the treatment of patients with HR+/HER2- early breast cancer.

Dennis J. Slamon, MD, discusses the key findings from the phase 3 NATALEE trial of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.

Dennis J. Slamon, MD, PhD, discusses the subgroup benefits and safety profile of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.